HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral propranolol and intravitreal ranibizumab for refractory serous macular detachment secondary to retinal capillary hemangioblastoma.

AuthorsP Hernández-Martínez, R Gallego-Pinazo, R Dolz-Marco, J F Arevalo, M Díaz-Llopis, A Cisneros Lanuza
JournalArchivos de la Sociedad Espanola de Oftalmologia (Arch Soc Esp Oftalmol) Vol. 90 Issue 8 Pg. 399-401 (Aug 2015) ISSN: 1989-7286 [Electronic] Spain
PMID25433416 (Publication Type: Case Reports, Letter)
Chemical References
  • Adrenergic beta-Antagonists
  • Angiogenesis Inhibitors
  • Propranolol
  • Ranibizumab
Topics
  • Administration, Oral
  • Adrenergic beta-Antagonists (administration & dosage, therapeutic use)
  • Adult
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Hemangioblastoma (complications)
  • Humans
  • Intravitreal Injections
  • Laser Coagulation
  • Male
  • Propranolol (administration & dosage, therapeutic use)
  • Ranibizumab (administration & dosage, therapeutic use)
  • Recurrence
  • Retinal Detachment (drug therapy, etiology, surgery)
  • Retinal Neoplasms (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: